ALPHA YOUNG LLC
Biotech · Private
Recombinant soluble klotho (sKL) protein therapeutic with enhanced stability and bioactivity for chronic kidney disease
- Grants
- $2.0M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Design of a bioactive mimetic of soluble klotho for the treatment of chronic kidney disease | $256,050 | |
| Federal grant | Department of Health and Human Services · Phase II · Design of a bioactive mimetic of soluble klotho for the treatment of chronic kidney disease | $606,474 | |
| Federal grant | Department of Health and Human Services · Phase II · Design of a bioactive mimetic of soluble klotho for the treatment of chronic kidney disease | $543,558 | |
| Federal grant | Department of Health and Human Services · Phase II · Design of a bioactive mimetic of soluble klotho for the treatment of chronic kidney disease | $548,801 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2002 | Regulonix | — | — |
| 2003 | FORMATION VENTURE ENGINEERING FOUNDRY INC | — | — |
| 2004 | Converge Bio Inc. | — | $25M |
| 2005 | ALPHA YOUNG LLC | — | — |
| 2006 | Dispatch Biotherapeutics | — | — |
| 2007 | OROX BIOSCIENCES, INC. | — | — |
| 2008 | cAMPfield Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.